Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$5.5 million.

  • Enanta Pharmaceuticals' Net Cash Flow fell 958.30% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 88.49%. This contributed to the annual value of -$5.5 million for FY2025, which is 88.49% up from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Net Cash Flow is -$5.5 million, which was up 88.49% from -$48.2 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Net Cash Flow ranged from a high of $41.4 million in FY2023 and a low of -$48.2 million during FY2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$5.5 million (2025), whereas its average is -$4.1 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 520.16% in 2023, then plummeted by 216.33% in 2024.
  • Enanta Pharmaceuticals' Net Cash Flow (Yearly) stood at -$29.9 million in 2021, then surged by 67.08% to -$9.9 million in 2022, then spiked by 520.16% to $41.4 million in 2023, then plummeted by 216.33% to -$48.2 million in 2024, then soared by 88.49% to -$5.5 million in 2025.